Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy and adjuvant pembro or pbo for early stage NSCLC: Subgroup analyses of the phase III KEYNOTE-671 study
Neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy and adjuvant pembro or pbo for early stage NSCLC: Subgroup analyses of the phase III KEYNOTE-671 study Garassino, M. C., Gao, S., Liberman, M., Spicer, J. D., Chen, K., Vanakesa, T., Thiberville, L., Chaves, F. F., Liu, G., Okada, M., Saji, H., Laktionov, K., Rittmeyer, A., Bosch-Barrera, J., Gentzler, R. D., Ganti, A. K., Jensen, E., Keller, S. M., Samkari, A., Wakelee, H. ELSEVIER. 2024: S778-S779View details for DOI 10.1016/j.annonc.2024.08.1269
View details for Web of Science ID 001326612901513